Needed: New and Better Tools to Combat Latent Tuberculosis Infection
2008; American College of Physicians; Volume: 149; Issue: 10 Linguagem: Inglês
10.7326/0003-4819-149-10-200811180-00011
ISSN1539-3704
Autores Tópico(s)Mycobacterium research and diagnosis
ResumoEditorials18 November 2008Needed: New and Better Tools to Combat Latent Tuberculosis InfectionHenry M. Blumberg, MDHenry M. Blumberg, MDFrom Emory University School of Medicine, Atlanta, GA 30303.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-149-10-200811180-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Treatment of latent tuberculosis infection (LTBI) is a major strategy for tuberculosis control in the United States, Canada, and selected resource-intensive countries (1, 2). Given the decline in tuberculosis cases in the United States since 1992, interest in treating patients with LTBI is renewed in order to eliminate the large reservoir of individuals at risk for progression to tuberculosis (1, 3). The Centers for Disease Control and Prevention, such professional organizations as the American Thoracic Society and the Infectious Diseases Society of America, and others (13) recommend targeted testing of persons at increased risk for tuberculosis and provision of therapy ...References1. . Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49:1-51. [PMID: 10881762] MedlineGoogle Scholar2. Canadian Thoracic Society and Public Health Agency of Canada. Canadian Tuberculosis Standards, 6th ed. 2007. Accessed at www.phac-aspc.gc.ca/tbpc-latb/pubs/pdf/tbstand07_e.pdf on 15 October 2008. Google Scholar3. Blumberg HM, Leonard MK, and Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA. 2005;293:2776-84. [PMID: 15941808] CrossrefMedlineGoogle Scholar4. Sterling TR. New approaches to the treatment of latent tuberculosis. Semin Respir Crit Care Med. 2008;29:532-41. [PMID: 18810686] CrossrefMedlineGoogle Scholar5. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, and Hafner R; Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA. 2000;283:1445-50. [PMID: 10732934] MedlineGoogle Scholar6. Centers for Disease Control and Prevention (CDC). Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infectionUnited States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:735-9. [PMID: 12904741] MedlineGoogle Scholar7. Hong Kong Chest Service/Tuberculosis Research Centre. Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992;145:36-41. [PMID: 1731596] CrossrefMedlineGoogle Scholar8. Menzies D, Long R, Trajman A, Dion MJ, Yang J, and Al Jahdali A; Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection. A randomized trial. Ann Intern Med. 2008;149:689-97. LinkGoogle Scholar9. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3:847-50. [PMID: 10524579] MedlineGoogle Scholar10. Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, and O'Connell JJ; Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med. 1996;154:1473-7. [PMID: 8912767] CrossrefMedlineGoogle Scholar11. Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, and Meador J; Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med. 1997;155:1735-8. [PMID: 9154885] CrossrefMedlineGoogle Scholar12. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, and Federline L; Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166:1863-70. [PMID: 17000943] CrossrefMedlineGoogle Scholar13. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, and Friedman LN; American Thoracic Society. Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603-62. [PMID: 12588714] CrossrefMedlineGoogle Scholar14. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, and Vittinghoff E; Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002;137:640-7 LinkGoogle Scholar15. Baciewicz AM, Chrisman CR, Finch CK, and Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci. 2008;335:126-36. [PMID: 18277121] CrossrefMedlineGoogle Scholar16. Byrd RB, Horn BR, Solomon DA, and Griggs GA. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1, 000 patients. JAMA. 1979;241:1239-41. [PMID: 762788] CrossrefMedlineGoogle Scholar17. Kopanoff DE, Snider DE, and Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978;117:991-1001. [PMID: 666111] MedlineGoogle Scholar18. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, and Mugyenyi P; A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med. 1997;337:801-8. [PMID: 9295239] CrossrefMedlineGoogle Scholar19. Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, and Metsou F; The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45:715-22. [PMID: 17712755] CrossrefMedlineGoogle Scholar20. Sterling TR, Hackman J, Horsburgh CR, Chaisson RE, Wang YC, Quinn E, et al. Tuberculosis Trials Consortium. Design of Tuberculosis Trials Consortium Study 26: once-weekly rifapentine plus isoniazid (INH) for 3 months vs. daily INH for 9 months for the treatment of latent TB infection. Presented at the 4th World Congress on Tuberculosis, Washington, DC, 3-5 June 2002: Abstract 143. Google Scholar21. Bennett DE, Courval JM, Onorato I, Agerton T, Gibson JD, and Lambert L; Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med. 2008;177:348-55. [PMID: 17989346] CrossrefMedlineGoogle Scholar22. Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, and Horsburgh CR; Tuberculosis Epidemiologic Studies Consortium. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med. 2006;173:927-31. [PMID: 16424442] CrossrefMedlineGoogle Scholar23. Burman W, McNeeley D, Moulton LH, Spigelman M, and Vernon A. Advancing the science in clinical trials for new TB drugs [Editorial]. Int J Tuberc Lung Dis. 2008;12:111-2. [PMID: 18230241] MedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Henry M. Blumberg, MDAffiliations: From Emory University School of Medicine, Atlanta, GA 30303.Grant Support: By the National Institutes of Health/Fogarty International Center (D43TW007124) and National Institutes of Health/National Center for Research Resources (UL1RR025008).Disclosures: None disclosed.Corresponding Author: Henry M. Blumberg, MD, Division of Infectious Diseases, Emory University School of Medicine, 49 Jesse Hill Jr. Drive, Atlanta, GA 30303; e-mail, [email protected]. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAdverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection Dick Menzies , Richard Long , Anete Trajman , Marie-Jose Dion , Jae Yang , Hamdan Al Jahdali , Ziad Memish , Kamran Khan , Michael Gardam , Vernon Hoeppner , Andrea Benedetti , and Kevin Schwartzman Metrics 18 November 2008Volume 149, Issue 10Page: 761-763KeywordsAdverse eventsAdverse reactionsAlanineAminotransferasesClinical trialsDeath ratesDiabetes mellitusDrug interactionsDrugsHIV infectionsImmunosuppressivesInfectious diseasesIsoniazidMedical risk factorsMycobacterium tuberculosisPrevention, policy, and public healthRenal failureSilicosisTuberculosis ePublished: 18 November 2008 Issue Published: 18 November 2008 Copyright & PermissionsCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Referência(s)